Neuroene Therapeutics was formed in 2015 after the Co-Founders discovered a new class of compounds that improve mitochondrial health in multiple animal models of difficult to treat neurological diseases. Our long-term objective is to develop our mitochondrial modulator drug discovery platform to identify clinical candidates for diseases of underlying mitochondrial dysfunction. Neuroene Therapeutics’ portfolio includes issued and pending patents covering hundreds of analogs aimed at the treatment of numerous disease indications and the corresponding methods. The 1000 sq. ft. Neuroene Therapeutics laboratory is located at 645 Meeting Street, Suite 10, Charleston, SC 29403, in downtown Charleston at the South Carolina Research Authority/Medical University of South Carolina Innovation Center incubator facility.
C. James Chou, Ph.D. Dr. Chou has BS and BA degrees in Biochemistry and Economics (dual diploma, U. Washington), and previously ran a non-profit organization focusing on after school programs. After his Ph.D. in Chemistry (U. Washington) he joined Dr. Joel Gottesfeld’s group at the Scripps Research Institute (CA) where he developed disease modifying treatments for diseases such as for Friedreich’s Ataxia, a rare mitochondrial disease (which has completed phase II clinical trial in Europe). Dr. Chou splits his time between his academic laboratory at the Medical University of South Carolina and Neuroene Therapeutics, where he oversees the chemistry and business ends of the company.
Sherine Chan, Ph.D. Dr. Chan has been in the mitochondrial field since 1996 and has degrees in Veterinary Biology (BS Hons. Murdoch University, Australia) and Clinical Biochemistry (PhD, U. Western Australia), and a postdoctoral fellowship at the National Institutes of Health, which focused on mitochondrial diseases using in vitrobiochemistry, mitochondrial disease patient cells, and in vivo mouse models of mitochondrial dysfunction focused on dysfunction in the heart. At the Medical University of South Carolina, her group has developed new zebrafish models and assays of mitochondrial dysfunction, including models that affect mitochondrial quality control in the heart. Dr. Chan is primarily employed at Neuroene Therapeutics, and she oversees the biological component of the company as well as raising awareness and funds for the company.
Richard Himes, Ph.D. Dr. Himes joined Neuroene Therapeutics in 2016 and brings to the company his expertise in chemical synthesis, organic and bioinorganic chemistry, and developing small-molecule chemistry for neurological diseases.After obtaining his PhD from Purdue University, Dr. Himes joined Dr. Kenneth Karlin’s research group at Johns Hopkins University where he performed cutting-edge research on redox active compounds in Alzheimer’s disease. Dr. Himes teaches and runs research teams on organic synthesis at the College of Charleston, and he performs much of the medicinal chemistry for the company as well as providing scientific oversight.